Lantheus
LNTH
Hutchmed (China)
HCM
Workday
WDAY
DexCom
DXCM
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 100.77%67.96M | |||||||||
Net income from continuing operations | ---- | ---- | ---- | ---- | ---- | 91.22%69.41M | ---- | ---- | ---- | ---- |
Operating gains losses | ---- | ---- | ---- | ---- | ---- | -66.16%-15.86M | ---- | ---- | ---- | ---- |
Depreciation and amortization | ---- | ---- | ---- | ---- | ---- | 59.39%14.79M | ---- | ---- | ---- | ---- |
Other non cash items | ---- | ---- | ---- | ---- | ---- | -241.47%-1.3M | ---- | ---- | ---- | ---- |
Change In working capital | ---- | ---- | ---- | ---- | ---- | 144.60%855K | ---- | ---- | ---- | ---- |
-Change in receivables | ---- | ---- | ---- | ---- | ---- | 115.61%830K | ---- | ---- | ---- | ---- |
-Change in inventory | ---- | ---- | ---- | ---- | ---- | -33.23%834K | ---- | ---- | ---- | ---- |
-Change in prepaid assets | ---- | ---- | ---- | ---- | ---- | 147.54%406K | ---- | ---- | ---- | ---- |
-Change in payables and accrued expense | ---- | ---- | ---- | ---- | ---- | -99.14%13K | ---- | ---- | ---- | ---- |
-Change in other current assets | ---- | ---- | ---- | ---- | ---- | 23.64%136K | ---- | ---- | ---- | ---- |
-Change in other current liabilities | ---- | ---- | ---- | ---- | ---- | 77.78%-6K | ---- | ---- | ---- | ---- |
-Change in other working capital | ---- | ---- | ---- | ---- | ---- | -195.90%-1.36M | ---- | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -11.86%59.9M | 30.14%12.06M | -9.70%16.15M | -35.14%14.35M | -7.17%17.34M | 100.77%67.96M | -60.88%9.26M | 52.05%17.88M | 875.32%22.13M | 583.54%18.68M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 122.77%25.72M | |||||||||
Net PPE purchase and sale | ---- | ---- | ---- | ---- | ---- | 122.77%25.72M | ---- | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -284.34%-47.42M | -120.56%-7.7M | -3,467.51%-7.03M | 8.61%-10.18M | -5,856.35%-22.52M | 122.77%25.72M | 147.91%37.43M | 99.36%-197K | -289.54%-11.13M | 67.44%-378K |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -159.62%-65.14M | |||||||||
Net issuance payments of debt | ---- | ---- | ---- | ---- | ---- | -188.04%-73.28M | ---- | ---- | ---- | ---- |
Net common stock issuance | ---- | ---- | ---- | ---- | ---- | -66.43%9.36M | ---- | ---- | ---- | ---- |
Net preferred stock issuance | ---- | ---- | ---- | ---- | ---- | --482K | ---- | ---- | ---- | ---- |
Cash dividends paid | ---- | ---- | ---- | ---- | ---- | -100.74%-1.89M | ---- | ---- | ---- | ---- |
Proceeds from stock option exercised by employees | ---- | ---- | ---- | ---- | ---- | --330K | ---- | ---- | ---- | ---- |
Net other financing activities | ---- | ---- | ---- | ---- | ---- | 84.98%-140K | ---- | ---- | ---- | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 85.52%-9.43M | 95.98%-2.57M | 22.61%-2.34M | 66.23%-2.18M | -128.63%-2.34M | -159.62%-65.14M | -208.71%-63.82M | -107.33%-3.03M | -214.01%-6.47M | 124.94%8.18M |
Net cash flow | ||||||||||
Beginning cash position | ---- | ---- | ---- | ---- | ---- | 314.94%39.73M | ---- | ---- | ---- | ---- |
Current changes in cash | ---- | ---- | ---- | ---- | ---- | -5.34%28.54M | ---- | ---- | ---- | ---- |
End cash Position | ---- | ---- | ---- | ---- | ---- | 71.84%68.27M | ---- | ---- | ---- | ---- |
Free cash flow | 6.88%59.9M | 554.56%12.06M | -9.70%16.15M | -272.68%-18.34M | -7.17%17.34M | 150.16%56.04M | 97.82%-2.65M | 52.05%17.88M | 1,902.89%10.62M | 471.80%18.68M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |